RSL3: A Potent GPX4 Inhibitor for Ferroptosis Induction in Cancer Research

Executive Summary: RSL3 (glutathione peroxidase 4 inhibitor) is a synthetic small molecule that irreversibly inhibits GPX4, a selenoenzyme key for cellular defense against lipid peroxidation (Saini et al., 2023). By blocking GPX4, RSL3 induces ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxide accumulation [Fig. 1]. RSL3 displays synthetic lethality with oncogenic RAS mutations in preclinical models, rapidly inhibiting tumor growth at low nanomolar concentrations (APExBIO). Its effects are caspase-independent, and can be reversed by overexpression of GPX4 or iron chelators. RSL3’s solubility profile, storage requirements, and dose-dependent safety in animal models make it a versatile tool for dissecting ferroptosis and oxidative stress pathways in cancer biology [Product page].

Biological Rationale

Cancer cells frequently acquire resistance to apoptosis, complicating effective treatment (Saini et al., 2023). Ferroptosis is a non-apoptotic, iron-dependent programmed cell death mechanism driven by the accumulation of lethal lipid peroxides. Glutathione peroxidase 4 (GPX4) is essential for detoxifying these lipid peroxides using glutathione (GSH) as a cofactor. Inhibition of GPX4 disrupts redox homeostasis, triggering ferroptotic death, particularly in therapy-resistant and RAS-mutant tumor cells [Table 2]. This mechanistic divergence from apoptosis underpins the use of RSL3 to study and exploit redox vulnerabilities in cancer, as explored in related reviews (contrast: further clarifies in vivo efficacy).

Mechanism of Action of RSL3 (glutathione peroxidase 4 inhibitor)

RSL3 is a direct, covalent inhibitor of GPX4. This selenoenzyme reduces toxic lipid hydroperoxides to non-toxic lipid alcohols in a GSH-dependent reaction [Fig. 3]. RSL3 binds the active site selenocysteine of GPX4, inactivating its peroxidase activity (APExBIO). This leads to:

• Accumulation of intracellular lipid peroxides.
• Increase in reactive oxygen species (ROS).
• Iron-dependent cell death (ferroptosis), distinct from caspase-dependent apoptosis.

Ferroptosis driven by RSL3 is characterized by morphological changes such as smaller mitochondria with increased membrane density, without chromatin condensation [Supplementary Fig. S4]. Overexpression of GPX4 or treatment with iron chelators (e.g., deferoxamine) can prevent RSL3-induced ferroptosis (expands: adds troubleshooting and application notes).

Evidence & Benchmarks

• RSL3 treatment (0.01–1 µM) induces ferroptosis in RAS-mutant cancer cell lines, as measured by lipid ROS accumulation and cell viability assays (Saini et al., 2023, Fig. 2A).
• Loss of GPX4 function is both necessary and sufficient for ferroptosis; rescue experiments with GPX4 overexpression block RSL3-mediated cell death (Fig. 4B).
• In vivo, subcutaneous administration of RSL3 (up to 400 mg/kg) reduces tumor volume in BJeLR xenograft nude mice models, with no observable systemic toxicity (APExBIO product data).
• Ferroptosis induction by RSL3 is independent of caspase activation and is reversed by lipophilic antioxidants or iron chelators (Table 3).
• PERK inhibition (a UPR arm) further sensitizes colorectal cancer cells to RSL3-induced ferroptosis by downregulating SLC7A11 and reducing GSH synthesis (Fig. 5D).

Applications, Limits & Misconceptions

RSL3, supplied by APExBIO, is widely used in cancer research to dissect ferroptosis signaling pathways, model synthetic lethality with RAS mutations, and test redox-targeting therapeutics. Its specificity for GPX4 allows for precise interrogation of oxidative stress and lipid peroxidation in experimental systems. In contrast to prior reviews (this article provides updated evidence from in vivo benchmarks), this dossier emphasizes quantitative, in vivo efficacy and workflow considerations.

Common Pitfalls or Misconceptions

• RSL3 is not a pan-oxidant or general ROS inducer; it specifically targets GPX4, not upstream antioxidant systems.
• It is ineffective in GPX4-null or knockout models, as the target is absent.
• Ferroptosis induced by RSL3 does not involve caspase activation; conventional apoptosis inhibitors do not block its effects.
• RSL3 is poorly soluble in aqueous buffers and ethanol; DMSO is required for stock solutions (≥125.4 mg/mL).
• Not all cancer cells are equally sensitive; RAS-mutant and therapy-resistant lines are most responsive (Table 1).

Workflow Integration & Parameters

For cell-based assays, dissolve RSL3 in DMSO to prepare stock solutions (≥125.4 mg/mL). Store powder at –20°C; prepare fresh aliquots before use. Warm and sonicate if needed to improve solubility. Typical working concentrations range from 10 nM to 1 µM. Optimal dosing must be empirically determined for each cell type. For in vivo use, subcutaneous injection at doses up to 400 mg/kg in mice has shown efficacy without toxicity. Always include iron chelators and GPX4 overexpression controls. Refer to the B6095 kit documentation for lot-specific details (APExBIO).

For an advanced analysis of troubleshooting and maximizing impact in oxidative stress modulation, see this workflow guide (this article provides more detailed benchmarks and pharmacology data).

Conclusion & Outlook

RSL3 is a validated, selective GPX4 inhibitor and ferroptosis inducer with robust applications in cancer biology. Its mechanism, in vivo efficacy, and defined workflow make it an essential tool for investigating ROS-mediated, iron-dependent cell death. As research advances, RSL3 will remain central to efforts targeting redox vulnerabilities in RAS-driven and therapy-resistant tumors. For ordering and technical details, visit the official APExBIO product page.